---
schema_version: "secwatch.filing_event.v1"
accession: "0001387131-23-012324"
form_type: "8-K"
ticker: null
cik: "0000887247"
company_name: "DMK PHARMACEUTICALS Corp"
filed_at: "2023-10-17T23:59:59+00:00"
generated_at: "2026-06-09T22:59:56.379690+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# DMK Pharmaceuticals receives Nasdaq delisting notice for failing to meet $35M market value requirement

## Summary
- On Oct 11, 2023, DMK received Nasdaq delisting notice for failing to maintain minimum $35M market value for 30 consecutive trading days.
- Company plans to timely request a hearing before Nasdaq Hearings Panel to stay delisting.
- Previously, on Apr 12, 2023, DMK was given 180 days to regain compliance, which expired Oct 9, 2023.
- No assurance that panel will grant continued listing or that DMK will regain compliance.

## SEC filing metadata
- accession: 0001387131-23-012324
- form_type: 8-K
- cik: 0000887247
- company_name: DMK PHARMACEUTICALS Corp
- filed_at: 2023-10-17T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887247/000138713123012324/0001387131-23-012324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887247/000138713123012324/dmk-8k_101123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001387131-23-012324
- JSON: https://secwatch.observer/filing/0001387131-23-012324.json
- Plain text: https://secwatch.observer/filing/0001387131-23-012324.txt

## Key facts
- Listing & Compliance Notices
  DMK PHARMACEUTICALS Corp received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: October 11, 2023, the Company received notice from the Staff that the Company’s common stock was subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq at least until the hearing is held and any extension the Panel may grant to the Company following the hearing expires. There can be no assurance, however, that the Panel will grant the Company’s request for continued listing or that the Company will regain compliance with
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123012324/0001387131-23-012324-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.